Aug 21 (Reuters) - Ionis Pharmaceuticals Inc IONS.O:
DAWNZERA™ (DONIDALORSEN) APPROVED IN THE U.S. AS FIRST AND ONLY RNA-TARGETED PROPHYLACTIC TREATMENT FOR HEREDITARY ANGIOEDEMA
IONIS PHARMACEUTICALS INC: DAWNZERA WILL BE AVAILABLE IN U.S. IN COMING DAYS